Project Grant K02DA060357

Award Date 6/1/24
Completion Date 5/31/28
Dollars Obligated $124K
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Chicago, IL 60611, USA
Similar Awards
This $189,500 Project Grant awarded by the National Institute on Drug Abuse (NIDA) under CFDA Program 93.279 - Drug Use and Addiction Research Programs aims to determine the extent to which cardiovascular disease (CVD) affects individuals with opioid use disorder (OUD) and how patients, providers, and payers can prevent CVD in this population. The key objectives are to: 1) examine the relationship between OUD and time to major adverse cardiovascular events (MACE), 2) identify barriers and...
This Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) provides $844,475 to the University of Alabama at Birmingham (UAB) to test a bundled intervention aimed at increasing treatment uptake for patients with opioid use disorder (OUD) and nonfatal opioid overdoses after emergency department (ED) discharge. The proposed intervention combines telehealth, peer support, buprenorphine prescribing, and linkage to...
This Project Grant award of $1,377,306 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will fund a multi-jurisdictional study to transform the evidence base on the prevalence of opioid use disorder (OUD) and the impact of opioid agonist treatment (OAT) as a strategy to prevent opioid-related harms. The study will leverage data linkages in the U.S. (Rhode Island, Wisconsin, Colorado, and Massachusetts), Australia (New South...
This K01 career development award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), is designed to provide Dr. Erath with mentored training in implementation science to become an independent investigator focused on advancing the implementation of evidence-based treatments for stimulant use disorder and other substance use disorders in harm reduction and community treatment settings. The total award amount is $194,098, with a...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $192,780 to The Leland Stanford Junior University to study factors associated with discontinuation of medications for opioid use disorder (MOUD) after surgery and the impact on patient outcomes. The key objectives are to: 1) identify risk factors for MOUD discontinuation after surgery and develop a predictive model, and 2) estimate the...
This $385,000 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to advance integrated treatment for co-occurring opioid use disorder (OUD) and alcohol use disorder (AUD) in real-world settings. The key objectives are to: Assess the effectiveness of integrated treatment approaches, including first-line medications and glucagon-like peptide-1 receptor agonists (GLP-1 RAs), for patients with co-occurring OUD...
This Project Grant award, funded by the National Institute on Drug Abuse (NIDA) under CFDA 93.279 - Drug Use and Addiction Research Programs, aims to evaluate the implementation of a pharmacist-integrated model of opioid use disorder (OUD) treatment to increase naloxone co-prescribing in primary care settings. The $193,336 award to Trustees of Dartmouth College, with a project period from September 2024 to May 2026, will fund research to: 1) describe federal, state, and clinic-level policies and...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $196,236 to The Washington University to conduct research focused on disparities in the prescription and effectiveness of medications to treat opioid use disorder (OUD) during pregnancy. The key objectives of the 5-year project are to: 1) evaluate how race and racial segregation are associated with the use of buprenorphine and methadone as well...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to develop and pilot test the "Patient Reported Outcome Measures to Individualize Treatment and Improve Retention" (RETAIN) program intervention package. The RETAIN program seeks to capture patient-reported outcome measures (PROMs) in federally-qualified health center (FQHC)-based opioid use disorder (OUD) treatment to improve patient...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $197,748 to The Regents of the University of California, San Francisco to develop and pilot an enhanced low-dose buprenorphine initiation (LDI) program. The goal is to improve treatment outcomes for individuals with opioid use disorder, particularly those using fentanyl, by overcoming barriers to successful buprenorphine initiation and...

RESEARCH CAREER ENHANCEMENT IN IMPLEMENTATION SCIENCE TO ADDRESS PRIMARY PREVENTION, HARM REDUCTION, AND EVIDENCE-BASED INTERVENTIONS FOR OPIOID USE DISORDER FROM THE EMERGENCY DEPARTMENT - PROJECT SUMMARY THE EMERGENCY DEPARTMENT (ED) HAS EMERGED AS A CRITICAL CONTEXT FROM WHICH TO ADDRESS THE U.S. OPIOID OVERDOSE CRISIS, WHICH IN 2021 ALONE ACCOUNTED FOR OVER 80,000 DEATHS. THIS K02 INDEPENDENT SCIENTIST AWARD WILL ENHANCE MY RESEARCH CAREER WITH IMPLEMENTATION SCIENCE APPROACHES TO ADDRESS MULTIPLE DOMAINS OF THE HHS OVERDOSE PREVENTION STRATEGY FROM THE EMERGENCY CARE SETTING. DURING THIS K02 AWARD, I WILL AUGMENT MY EXISTING CLINICAL EXPERTISE IN EMERGENCY MEDICINE AND ADDICTION MEDICINE AND CURRENT RESEARCH PORTFOLIO SPANNING THE CONTINUUM OF OPIOID USE AND OPIOID USE DISORDER WITH (1) NEW SKILLS, KNOWLEDGE, AND TRAINING IN IMPLEMENTATION SCIENCE, (2) ADVANCED PROFICIENCY IN CLINICAL TRIAL DESIGN, AND (3) SPECIALIZED PROFESSIONAL DEVELOPMENT IN TEAM LEADERSHIP AND MANAGEMENT. TO ACCOMPLISH THESE TRAINING OBJECTIVES, I WILL LEVERAGE MY ONGOING R01-FUNDED SINGLE SITE RANDOMIZED TRIAL EVALUATING AN EMBEDDED ED PHYSICAL THERAPY INTERVENTION AS A NON-OPIOID TREATMENT MODALITY FOR LOW BACK PAIN (R01HS027426, NCT04921449), WHICH AFFECTS NEARLY 2 IN 5 PEOPLE AND IS THE MOST COMMON REASON FOR ACUTE AND CHRONIC OPIOID USE. SPECIFICALLY, I WILL (1) EVALUATE IMPLEMENTATION OUTCOMES ACROSS MULTIPLE PARTNERS ENGAGED IN MY ONGOING R01 TRIAL, (2) GATHER QUALITATIVE DATA ON CONTEXTUAL IMPLEMENTATION DETERMINANTS AND PREFERRED IMPLEMENTATION STRATEGIES AMONG CURRENT AND FUTURE RESEARCH PARTNERS FOR USE IN A FUTURE MULTI-SITE HYBRID EFFECTIVENESS-IMPLEMENTATION TRIAL, AND (3) CONDUCT A MIXED-METHODS COST ANALYSIS OF THE EMBEDDED ED PHYSICAL THERAPY CARE MODEL TO FACILITATE ITS SCALABILITY AND LONG-TERM SUSTAINABILITY. THIS K02 AWARD COMES AT AN OPPORTUNE TIME IN MY EARLY- TO MID-CAREER TRANSITION, AS IT WILL PROVIDE ME WITH A FOUR-YEAR PERIOD OF INTENSIVE RESEARCH FOCUS TO CONDUCT THESE TRAINING AND RESEARCH ACTIVITIES, WHICH I COULD NOT OTHERWISE ACCOMPLISH GIVEN MY CURRENT CLINICAL OBLIGATIONS AS AN EMERGENCY MEDICINE PHYSICIAN. FOLLOWING COMPLETION OF THIS K02 AWARD, I WILL APPLY THE NEWLY ACQUIRED IMPLEMENTATION SCIENCE EXPERTISE TO ACCELERATE AND CATALYZE THE TRANSLATION OF MY RESEARCH AGENDA TO REAL-WORLD PRACTICE, INCLUDING PRIMARY PREVENTION, HARM REDUCTION, AND EVIDENCE-BASED INTERVENTIONS FOR OPIOID USE DISORDER FROM THE ED SETTING.

Posted 5/29/24, 12:00 AM